EDIT - Editas Medicine, Inc.
| Previous Close | 27.01 |
| Open | 26.92 |
| Bid | 26.30 x 900 |
| Ask | 27.75 x 1800 |
| Day's Range | 26.56 - 27.51 |
| 52 Week Range | 17.80 - 41.43 |
| Volume | 455,917 |
| Avg. Volume | 871,519 |
| Market Cap | 1.326B |
| Beta (3Y Monthly) | 2.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.34 |
| Earnings Date | May 1, 2019 - May 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.71 |
- Zacks•13 hours ago
Is a Beat in Store for Editas (EDIT) This Earnings Season?
On Editas' (EDIT) first-quarter earnings call, investor focus will be on the company's progress with its most advanced pipeline candidate, EDIT-101.
- Zacks•14 hours ago
Editas Medicine (EDIT) Expected to Beat Earnings Estimates: Should You Buy?
Editas (EDIT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GuruFocus.com•8 days ago
One-Size-Fits-All CRISPR Lock Could Catapult the Sector Forward
The three pure-play CRISPR stocks have been on the decline since early 2018. Shares of Intellia Therapeutics (NTLA), Editas Medicine (EDIT) and leader CRISPR Therapeutics (CRSP) have magnified the declines of the broader stock indexes late last year. Warning! GuruFocus has detected 3 Warning Signs with NTLA.
- Zacks•9 days ago
Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for a second indication - transfusion-dependent beta thalassemia.
- American City Business Journals•9 days ago
Bain Capital raising another life sciences fund after $720M debut
Bain Capital is in the process of raising money for a second life sciences fund, less than two years after it amassed $720 million for its inaugural fund targeting the fast-growing sector. Bain revealed the new fund in a securities filing last week. The filing does not say how much the Boston-based private equity firm is hoping to raise.
- Motley Fool•15 days ago
3 Top Small-Cap Stocks to Buy in April
Huami, Tanger, and Editas Medicine have small market caps, but that only leaves them more room for multibagger returns.
- Investopedia•16 days ago
These Cannabis and China ETFs are Leading the 2019 Rally
Stock investors seeking even bigger returns than the 2019 bull rally might look at five ETFs that have already gained at least 40% year-to-date, approaching triple the 15% pace of the S&P 500. The winners ...
- Motley Fool•17 days ago
How Editas Medicine Could Make You Better (and Richer)
If CRISPR therapies pan out, the possibilities are vast.
- Motley Fool•17 days ago
5 Stocks in the Age of Miracles
Motley Fool co-founder David Gardner shares five picks that are changing the world and bringing tomorrow closer to today.
- Motley Fool•18 days ago
3 Top Small-Cap Biotech Stocks for Aggressive Investors
They're risky, but these up-and-coming biotechs could be tremendous winners for investors willing to take on those risks.
- Zacks•21 days ago
Editas (EDIT) Inks Cross Licensing Agreement with BlueRock
Editas (EDIT) inks a research and cross licensing agreement with BlueRock Therapeutics, LP.
- Motley Fool•22 days ago
Why Editas Medicine Stock Popped 18.5% in March
The gene-editing specialist continues to move toward commercialization of its primary drug candidate.
- Investor's Business Daily•22 days ago
CRISPR Biotech Inks Deal To Use Stem Cells In Gene-Editing Medicine
Editas Medicine signed a collaboration deal with oncology player BlueRock Therapeutics on Wednesday — following in the footsteps of other CRISPR gene-editing companies. Editas stock lifted.
- GlobeNewswire•23 days ago
Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms
Editas Medicine, Inc. (EDIT), a leading genome editing company, and BlueRock Therapeutics, LP, a leading engineered cell therapy company, today announced a strategic research collaboration and cross-licensing agreement to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture novel engineered cell medicines. Genome editing and cell therapy technologies are rapidly advancing with the potential to significantly impact the future of medicine.
- Motley Fool•last month
Better Buy: Editas Medicine vs. Sangamo Therapeutics
Which of these struggling gene-editing biotechs is most likely to win over the long run?
- GlobeNewswire•last month
Research Report Identifies Spirit Airlines, Integrated Device Technology, Editas Medicine, MACOM Technology Solutions, Taylor Morrison Home, and Brunswick with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, March 26, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- InvestorPlace•last month
Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons
With so much attention pointing once again to the again-escalating U.S.-China trade dispute, it's easy to overlook Bio-Path Holdings (NASDAQ:BPTH). However, the oncology specialist is easily one of the best-performing investments of 2019. Year-to-date, BPTH stock has gained a mind-blowing near-500%.More importantly, a fundamental catalyst supports the dramatic rise in valuation. A favorable clinical trial of the company's acute myeloid leukemia drug lifted Bio-Path stock from the doldrums. This news has obvious positive implications, as this particular cancer has a market size of $701.6 million. Overall, leukemia's market value will likely hit $12 billion in a few years.At the same time, biotechnology firms are hardly stable investments. While BPTH stock currently enjoys the afterglow of a promising trial, it could just as easily go awry. After all, if cancer research was straightforward, we'd already have a cure.InvestorPlace - Stock Market News, Stock Advice & Trading TipsInvariably, though, the skyrocketing Bio-Path stock commands our attention. Should you buy into this winning streak, or is this hand destined to cool? Here are three pros and three cons to consider: Pro 1: A Possible Breakthrough Could Further Boost BPTH StockI'm not breaking new ground when I say that cancer is an uncomfortable subject. However, acute myeloid leukemia is a nasty strain. The disease spreads very rapidly if left untreated. By entering the bloodstream, this cancer can affect the liver, spleen, central nervous system, and testicles. * Top 7 Service Sector Stocks That Will Pay You to Own Them The latter may have caught the attention of Wall Street's men, who fueled the spike in BPTH stock.In all seriousness, though, the latest clinical trial offered encouraging data. Out of 17 patients in the study, 11 responded to Bio-Path's prexigebersen drug. And of those 11, five experienced a complete response. Pro 2: Bio-Path Stock Levers Profound TechnologiesA thousand years from now, I'm sure that our future progeny will look back on us with macabre fascination for how we treated cancer by blasting patients with radiation. I can't help but bring up the obvious question: doesn't radiation cause cancer?Fortunately, much smarter people than I have answered this inquiry. Bio-Path's solution is their proprietary DNAbilize platform. In short, this enables oncologists to precisely deliver cancer-killing therapies to affected cells without nuking the patient.Such technologies lever a broader impact on this industry. Some patients simply don't have the physical strength to endure chemotherapy or radiology. DNAbilize is a lifesaver on multiple fronts, further bolstering the case for Bio-Path stock. Pro 3: BPTH Probably Already Hit Rock-BottomI'm not always comfortable with the argument that a particular stock has priced in all the bad news. Unless you're privy to insider information -- at which point you shouldn't act on that info -- you just don't know if more nasty stuff lies ahead.However, I can't imagine BPTH stock falling even more than it already has. Bear in mind that shares used to trade for well over $500 just a few years ago. With that context, BPTH appears like a bargain, even with this year's mooning. Con 1: Shares Used to Trade at $500-plusOn one hand, the ability to buy Bio-Path stock for pennies on the dollar appeals to many contrarians. But those with a critical eye will argue that a reason exists for the meltdown.Let's look even further back. In early January 2014, BPTH stock was on the cusp of clearing $1,000. In May of 2008, and just prior to the Great Recession, it hit four digits.The argument that "it can't get any worse" failed these early investors "bigly." You don't want to repeat their mistake. Con 2: Bio-Path has Tough CompetitionWhile Bio-Path's DNAbilize platform appears profoundly impressive, it's not the only party in town. BPTH is riding the broader category of gene therapy, or the targeted delivery of disease-fighting therapies. But other names, including CRISPR Therapeutics (NASDAQ:CRSP), Roche Holding (OTCMKTS:RHHBY), and Editas Medicine (NASDAQ:EDIT) compete aggressively in this sector. * 5 Cloud Stocks to Help Your Portfolio Fly Given the historical volatility in BPTH stock, I want some reassuring factors that I can depend on. Unfortunately, Bio-Path doesn't have a moat, which makes me jittery about its sudden rise. Con 3: Biotech is Incredibly VolatileRight now, everyone has mad love for Bio-Path stock because of its unexpected ascent. However, I've seen this story play out before in this wild market segment. All it takes is one bad trial to undo years of effort and research.Plus, BPTH stock has two obstacles regarding its drug pipeline. Management must demonstrate that their therapies can consistently beat placebo, which is no easy task. Plus, they have to show that their solutions are superior to the competition. Again, that's no gimme. Bottom Line on BPTH StockAdmittedly, I see the both the technical and fundamental potential for BPTH, and I'm personally intrigued. However, I keep going back to the inherent volatility of the biotech industry and Bio-Path stock. Yes, it enjoyed a positive paradigm-shift, but it could just as easily go sour.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Invincible Stocks Leading The Bull Market Higher * 5 Dow Jones Stocks Coming to Life * 7 of the Best High-Yield Funds for 2019 and Beyond Compare Brokers The post Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons appeared first on InvestorPlace.
- Simply Wall St.•last month
What Do Investors Need To Know About Editas Medicine, Inc.’s (NASDAQ:EDIT) Earnings Outlook?
The latest earnings release Editas Medicine, Inc.'s (NASDAQ:EDIT) announced in December 2018 showed that losses became smaller relative to the prior year's level as a result of recent tailwinds BelowRead More...
- Motley Fool•last month
3 Stocks That Could Double Your Money
Here's why Wall Street thinks these stocks could generate returns of 100% or more in the next 12 months.
- Motley Fool•2 months ago
5 Top Gene-Editing Stocks for 2019
The future of treating disease might be gene editing, and these five stocks have the most promising technologies.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of EDIT earnings conference call or presentation 28-Feb-19 10:00pm GMT
Q4 2018 Editas Medicine Inc Earnings Call
- Zacks•2 months ago
S&P Reclaims 2800; NASDAQ’s Streak Hits 10 Weeks
S&P; Reclaims 2800; NASDAQ’s Streak Hits 10 Weeks
- Motley Fool•2 months ago
Why Editas Medicine Stock Soared Today
The genome-editing leader just delivered an exciting quarterly update.
- ETF Trends•2 months ago
A Specialty Biotech ETF Strengthens on Optimism Over CRISPR Advancements
A targeted biotechnology ETF strategy jumped Friday after Editas Medicine (NasdaqGS: EDIT) announced fourth quarter results, revealing its latest progress toward the commercialization of its EDIT-101 drug ...
